[[{“value”:”
Harvard spinout GRO Biosciences has a platform technology for engineering therapeutic proteins that won’t prompt an immune response against them. The startup’s lead program is a potential competitor to an Amgen gout drug acquired in a multi-billion dollar deal.
The post Aiming to Top Amgen in Gout, Startup GRObio Gets $60M to Enter the Clinic appeared first on MedCity News.
“}]]
